Our reports feature research and analysis on topics that matter most in digital health today. As technology continues to influence healthcare, our insights are designed to help you understand what comes next and make better decisions in digital health.
By embracing digital measures, pharma can accelerate drug development, improve patient outcomes. Pharma can and will continue to compete on assets, but should not compete on (digital) endpoints. We require industry collaborations in order to usher in a new era of medicine.
Digital measures have the potential to revolutionise drug development. However, pharma has been slow to fully utilise these measures due to their high costs and lack of standardised applications across therapeutic areas.
This report presents an expert-led analysis of the state of digital measures in drug development. More specifically, the report delves into:
Download the report to learn what our HealthXL community experts believe is in store for the future of digital measures in drug development and how best to prepare for it.
This report reevaluates the role of medical affairs in pharma and asks what may be holding them back from a greater role in digital health.The future success of medical affairs relies on this function becoming a strategic enabler of digital health activities in pharma.
Interacting with HCPs and working closely with R&D and commercial means no other function within pharma is as ideally situated to push for a greater uptake of digital health and align key external stakeholders for adoption.
In this report, we look at:
Digital health solutions have the potential to solve many healthcare problems. Yet despite initiatives to unlock the value of digital health for pharma over the last decade, we're yet to see success at scale.
At this critical point, it’s worth reflecting on what didn't work, how we can learn from past experiments, and how pharma can move from opportunistic to strategic digital initiatives with real impact.
In this report, experts from the HealthXL advisory team, pharma and digital health companies look at:
HealthXL community members and industry leaders from pharma, digital health companies and decentralized trials providers have come together to create this new open-access tool.
The tool helps sponsors select the best digital measurement technologies for clinical trial use in each particular trial.
It also offers vendors a way to prepare a documentation package to support the sponsor evaluation process.
Digital health is evolving and maturing at a rapid pace, moving from a niche area of healthcare to a central component and bringing with it new innovations and infrastructural hurdles. It was only a matter of time before the major global tech players began to make moves towards adding their own contributions to this field. In our Big Tech and Digital Health report, we take stock at this pivotal point in time to explore how major players in technology are approaching digital health, and putting their stamp on the future of healthcare.
To access the full report, log in or sign up to the HealthXL Platform today.
The Oncology community insights report brings you all the insights and recommendations from experts on partnerships, evidence, adoption and more. This in depth report is co-created by the HealthXL Digital Health in Oncology community through a series of meetings in 2021 and 2022.
In this report we examine potential routes to market for digital therapeutics and provide our insights on how each of these avenues will likely develop, which one you should choose, when and why. The report is peppered with inputs from the HealthXL DTx community too. The routes to market for digital therapeutics that are covered in this report include direct to consumer, pharma partnerships and also launch via employers alongside alternative routes.
The DTx community insights report brings you all the insights and recommendations from experts on partnerships, investments, adoption and more. This in depth report is co-created by the HealthXL Digital Therapeutics (DTx) community through a series of meetings in 2021 and 2022.
The goal of this open-source document is to guide both sponsors and vendors during the vendor selection process in the field of digitally enabled technologies that support clinical research programs. In addition, the aim is to ensure reliable quality for sponsors and their users offering vendors a way to prepare a documentation package to support the sponsor evaluation process.